EP Patent

EP4103546A1 — Polymorphs of elafibranor

Assigned to Genfit SA · Expires 2022-12-21 · 3y expired

What this patent protects

The present invention relates to novel crystalline forms of elafibranor.

USPTO Abstract

The present invention relates to novel crystalline forms of elafibranor.

Drugs covered by this patent

Iqirvo (ELAFIBRANOR) · Ipsen

Patent Metadata

Patent number: EP4103546A1
Jurisdiction: EP
Classification: —
Expires: 2022-12-21
Drug substance claim: No
Drug product claim: No
Assignee: Genfit SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.